Bristol Myers Squibb’s recent acquisition of the former Eli Lilly partner Amylin Pharmaceuticals probably won’t have an effect on the share price of Novo Nordisk. Because, even though the deal could have a positive effect on the value of Novo Nordisk’s GLP-1 segment, the Novo share is already valued fairly high.
There is, however, a good chance that the Danish biotech company Zealand Pharma could cash in on the deal, as the French pharmaceutical group Sanofi is no longer in the running to take over Amylin’s GLP-1 products Buetta and Bydureon. That is the assessment of analyst Michael Friis Jørgensen from Alm. Brand Markets.